Seroquel (quetiapine) causes weight gain through several overlapping mechanisms: it blocks brain receptors that regulate appetite and satiety, disrupts how your body processes insulin and glucose, shifts your body composition in ways that slow your metabolism, and alters the hormones that tell you when you’re hungry or full. In clinical studies, patients on quetiapine gained an average of 2.5 kg (about 5.5 pounds) over one year, though individual results vary widely. Most of the gain happens in the first 12 weeks.
Histamine and Serotonin Receptor Blocking
The most immediate driver of weight gain is quetiapine’s effect on two types of brain receptors: histamine H1 receptors and serotonin 5-HT2C receptors. Both of these normally play a role in suppressing appetite and signaling fullness after eating. Quetiapine binds to and blocks both of them.
When H1 receptors are blocked, the result is increased appetite and cravings, particularly for carbohydrate-rich foods. This is the same receptor that older antihistamines (like Benadryl) block, which is why drowsiness and increased appetite are common side effects of those drugs too. The H1 blockade also contributes to the heavy sedation many people experience on Seroquel, which reduces physical activity and compounds the calorie imbalance.
Serotonin 5-HT2C receptors work differently but toward the same end. These receptors normally help your brain register that you’ve eaten enough. When quetiapine blocks them, that “I’m full” signal gets muted. You eat more before feeling satisfied, and you may find yourself snacking or eating larger portions without realizing the shift. Quetiapine also binds to several other receptor types, including dopamine D2, alpha-1 and alpha-2 adrenergic receptors, and additional serotonin subtypes, creating a broad pharmacological profile that touches multiple systems involved in energy balance.
Direct Effects on Insulin and Blood Sugar
Weight gain from Seroquel isn’t purely about eating more. Antipsychotics in this class can cause insulin resistance independently of food intake or body weight changes. This means your cells become less responsive to insulin, the hormone that moves sugar from your blood into your muscles and tissues for energy. When insulin signaling weakens, your body compensates by producing more insulin, which promotes fat storage.
At the cellular level, antipsychotics interfere with a key signaling chain inside muscle cells. They reduce the activity of a protein called Akt, which is essential for insulin to do its job. Research on related antipsychotics has shown reductions of 40 to 60 percent in critical steps of this signaling pathway. The result is that glucose stays in the bloodstream longer, insulin levels rise, and your body shifts toward storing energy as fat rather than burning it.
There’s also evidence that antipsychotics can directly damage the insulin-producing cells in the pancreas. They appear to interfere with insulin secretion through multiple receptor pathways and may even trigger those cells to self-destruct through a process called apoptosis. While much of this research has focused on olanzapine and clozapine (which carry the highest metabolic risk), quetiapine shares enough receptor activity to produce similar, if somewhat milder, effects.
Changes in Hunger Hormones
Quetiapine also reshapes the hormonal landscape that governs hunger and satiety. Two hormones matter most here: leptin and ghrelin. Leptin is produced by fat cells and signals your brain to stop eating. Ghrelin is released by the stomach and tells your brain you’re hungry.
In the early weeks of treatment with atypical antipsychotics, leptin levels rise rapidly. This sounds like it should reduce appetite, but the rise appears to reflect the body’s attempt to compensate for the drug’s appetite-stimulating effects rather than successfully counteracting them. Over time, the brain may become less sensitive to leptin’s signal, a pattern similar to what happens in obesity generally.
Ghrelin follows a different timeline. Levels tend to drop in the first few weeks of treatment, likely because patients are eating more and gaining weight. But in the longer term, ghrelin levels climb. One study of patients treated with atypical antipsychotics for at least one year found their active ghrelin levels were dramatically elevated compared to healthy controls: roughly 1,333 pg/ml versus 368 pg/ml. That’s more than three times the normal level of a hormone whose sole job is making you feel hungry. In one study comparing quetiapine directly with olanzapine and haloperidol over six weeks, the quetiapine group gained an average of 3.9 kg, compared with 8.4 kg for olanzapine and just 0.5 kg for the older antipsychotic haloperidol.
A Slower Metabolism
Beyond eating more and storing fat more readily, your body may actually burn fewer calories at rest while on quetiapine. A study following antipsychotic-naïve adolescents taking quetiapine, olanzapine, or risperidone over one year found that patients entered what researchers described as a “hypometabolic state.” Their resting energy expenditure, the calories burned just by existing, didn’t increase to match their growing body weight the way it normally would.
When the researchers adjusted for body weight, resting energy expenditure per kilogram dropped significantly. What happened was a shift in body composition: patients lost lean muscle mass (which burns more calories) relative to fat mass (which burns very little). So even though they weighed more, their bodies were burning energy less efficiently than predicted. This creates a frustrating cycle where the medication makes it harder to maintain weight even if you manage to control your food intake.
Does the Dose Matter?
You might expect higher doses to cause more weight gain, but the relationship isn’t straightforward. A comprehensive review of quetiapine and long-term weight change found no clear dose-dependent pattern. Patients on less than 200 mg per day gained an average of 1.54 kg, those on 200 to 399 mg gained 4.08 kg, those on 400 to 599 mg gained 1.89 kg, and those on 600 mg or more gained 3.57 kg. The lack of a clean upward trend suggests that even low doses activate enough of the relevant receptors to trigger metabolic changes.
This is particularly relevant for people prescribed low-dose Seroquel off-label for sleep. The sedating, appetite-stimulating H1 receptor blockade happens at lower doses than the antipsychotic effects, which means even 25 to 100 mg at bedtime can meaningfully increase appetite and promote weight gain over time.
How Seroquel Compares to Other Antipsychotics
Among second-generation antipsychotics, quetiapine falls in the middle of the weight gain spectrum. Clozapine and olanzapine consistently carry the highest risk, with olanzapine producing roughly twice the weight gain of quetiapine in head-to-head studies. Risperidone and aripiprazole generally cause less weight gain, and ziprasidone is considered the most weight-neutral option in this class. Quetiapine’s moderate risk profile means it’s neither the worst offender nor a safe bet metabolically.
Monitoring and What to Track
Current guidelines adapted from the American Diabetes Association and American Psychiatric Association recommend weighing in at baseline and then at weeks 4, 8, and 12 after starting quetiapine. After that, weight and BMI should be checked at least every three months. Waist circumference, which captures dangerous abdominal fat that BMI can miss, should be measured at baseline and annually. Screening for metabolic syndrome is recommended at baseline, four months after starting, and yearly thereafter.
In practice, tracking your own weight weekly during the first three months gives you the clearest picture of how the medication is affecting you. Since most weight gain clusters in those early weeks, catching a rapid upward trend early gives you and your prescriber the most options for adjusting the treatment plan before significant gain accumulates.